A urine specimen submitted by a member of this laboratory tested positive for amphetamine in both the EMIT screening and the EMIT confirmatory assays. Gas-chromatographic analysis indicated that the urine specimen was negative for amphetamine, methamphetamine, phentermine, phenylpropanolamine, and ephedrine. However, an early peak appeared on the chromatogram.
A urine specimen submitted by a member of this laboratory tested positive for amphetamine in both the EMIT screening and the EMIT confirmatory assays. Gas-chromatographic analysis indicated that the urine specimen was negative for amphetamine, methamphetamine, phentermine, phenylpropanolamine, and ephedrine. However, an early peak appeared on the chromatogram.
The subject occasionally used Midrin#{174} to treat migraine headaches. One component of this drug is isometheptene, a sympathomimetic amine. When isometheptene was tested for cross reactivity to the EMIT amphetamine antibody, specimens containing isometheptene at concentrations >5 mgfL tested positive.
To investigate the significance of this finding, an in vivo study was undertaken to determine how long after ingestion of two capsules the concentrations of isometheptene in urine would be of sufficient magnitude to produce a positive result by EMIT. Concentrations of isometheptene in urine were determined after a single-step alkaline extraction by gas chromatography (GC) (column packed with 10% Apiezon L with 2% KOH). EMIT assays were performed in duplicate in accordance with the manufacturer's instructions. We reanalyzed all positive specimens, using the EMIT confirmatory procedure for amphetamine.
The subject refrained from taking Midrin until submitted urine specimens were negative for isometheptene by CC. Two capsules were then ingested and urine specimens collected over a 48-h period. The urine specimen collected 3 h after ingestion was positive by the preliminary and confirmatory EMIT assays (isometheptene concentration by
